2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Other Solid Cancers

摘要

In patients with metastatic pancreatic cancer and germline mutations in BRCA1 or BRCA2, maintenance therapy with olaparib doubled the time to disease progression and the proportion of patients who were progression-free at 2 years, in the phase III POLO trial (Kindler et al., 2019). -"Maintenance olaparib provided a statistically significant and clinically meaningful 47% improvement in progression-free survival," said Hedy Lee Kindler, MD, Professor of Medicine at the University of Chicago, who presented the POLO trial findings at the 2019 ASCO Annual Meeting's Plenary Session. Patients receiving maintenance therapy after stable or responding disease to initial platinum-based chemotherapy had a median progression-free survival of 7.4 months, compared with 3.8 months for those on placebo (hazard ratio [HR] = 0.53; P = .0038).